S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
66,000% upside on tiny biotech? (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
66,000% upside on tiny biotech? (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
66,000% upside on tiny biotech? (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
Cactus Opens The Cash Flow Wellhead With Flexsteel Acquisition 
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday 6/9/2023
Kevin O'Leary Slams Martha Stewart's Comments on Remote Work: 'Nobody Wants to Work in These Places'
66,000% upside on tiny biotech? (Ad)
MarketBeat Week in Review – 6/4 - 6/9
New Mexico reaches $500M settlement with Walgreens in opioid case
66,000% upside on tiny biotech? (Ad)
Mark Zuckerberg Delivers Dorky Diss of Apple's Pricey New Headset
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
NASDAQ:DRRX

DURECT (DRRX) Stock Forecast, Price & News

$5.64
-0.11 (-1.91%)
(As of 06/9/2023 ET)
Compare
Today's Range
$5.60
$6.01
50-Day Range
$4.05
$7.00
52-Week Range
$3.16
$9.70
Volume
185,317 shs
Average Volume
146,469 shs
Market Capitalization
$138.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.25

DURECT MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
542.7% Upside
$36.25 Price Target
Short Interest
Healthy
1.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.19
Upright™ Environmental Score
News Sentiment
0.76mentions of DURECT in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.82) to ($0.68) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.18 out of 5 stars

Medical Sector

291st out of 988 stocks

Pharmaceutical Preparations Industry

129th out of 480 stocks


DRRX stock logo

About DURECT (NASDAQ:DRRX) Stock

DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

Receive DRRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.

DRRX Stock News Headlines

Save $200 on MarketBeat All Access
MarketBeat All Access is the premier all-in-one stock research solution that helps you identify the best stocks, monitor your portfolio, and keep track of the market. You get our top stock picks, best-in-class research tools, real-time alerts, proprietary research reports and much more. Claim your $200 account credit and free 30-day trial subscription today.
Analyst Ratings for Durect
8-K: DURECT CORP
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Durect: Q1 Earnings Snapshot
DURECT's (DRRX) "Buy" Rating Reaffirmed at HC Wainwright
H.C. Wainwright Reaffirms Their Buy Rating on Durect (DRRX)
Durect (NASDAQ: DRRX)
See More Headlines

DRRX Price History

DRRX Company Calendar

Last Earnings
11/01/2021
Today
6/10/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DRRX
Employees
79
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$36.25
High Stock Price Forecast
$44.00
Low Stock Price Forecast
$32.00
Forecasted Upside/Downside
+542.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-35,330,000.00
Net Margins
-187.82%
Pretax Margin
-187.82%

Debt

Sales & Book Value

Annual Sales
$19.28 million
Book Value
$1.10 per share

Miscellaneous

Free Float
23,388,000
Market Cap
$138.12 million
Optionable
Optionable
Beta
1.59

Key Executives

  • James E. Brown
    President, Chief Executive Officer & Director
  • Judy R. Joice
    Senior VP-Operations & Corporate Quality Assurance
  • Timothy M. Papp
    Chief Financial Officer & Secretary
  • Wei Qi Lin
    Executive Vice President-Research & Development
  • David J. Ellis
    Vice President-Clinical Development













DRRX Stock - Frequently Asked Questions

Should I buy or sell DURECT stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DRRX shares.
View DRRX analyst ratings
or view top-rated stocks.

What is DURECT's stock price forecast for 2023?

2 equities research analysts have issued 1 year price targets for DURECT's stock. Their DRRX share price forecasts range from $32.00 to $44.00. On average, they predict the company's share price to reach $36.25 in the next twelve months. This suggests a possible upside of 542.7% from the stock's current price.
View analysts price targets for DRRX
or view top-rated stocks among Wall Street analysts.

How have DRRX shares performed in 2023?

DURECT's stock was trading at $3.46 at the start of the year. Since then, DRRX shares have increased by 63.0% and is now trading at $5.64.
View the best growth stocks for 2023 here
.

When is DURECT's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our DRRX earnings forecast
.

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) issued its earnings results on Monday, November, 1st. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.10. The specialty pharmaceutical company earned $2.17 million during the quarter, compared to analysts' expectations of $2.18 million. DURECT had a negative trailing twelve-month return on equity of 130.41% and a negative net margin of 187.82%. During the same period in the prior year, the firm posted ($0.50) EPS.

When did DURECT's stock split?

DURECT's stock reverse split on the morning of Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM).

What is DURECT's stock symbol?

DURECT trades on the NASDAQ under the ticker symbol "DRRX."

Who are DURECT's major shareholders?

DURECT's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (4.96%), Armistice Capital LLC (2.49%), CM Management LLC (1.63%), Beirne Wealth Consulting Services LLC (1.16%), Renaissance Technologies LLC (1.12%) and Geode Capital Management LLC (0.88%). Insiders that own company stock include Gail J Maderis, Gail M Farfel, Judith J Robertson, Judy R Joice, Lp Bleichroeder, Mohammad Azab and Simon X Benito.
View institutional ownership trends
.

How do I buy shares of DURECT?

Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DURECT's stock price today?

One share of DRRX stock can currently be purchased for approximately $5.64.

How much money does DURECT make?

DURECT (NASDAQ:DRRX) has a market capitalization of $138.12 million and generates $19.28 million in revenue each year. The specialty pharmaceutical company earns $-35,330,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis.

How can I contact DURECT?

DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The official website for the company is www.durect.com. The specialty pharmaceutical company can be reached via phone at (408) 777-1417, via email at mike.arenberg@durect.com, or via fax at 408-777-3577.

This page (NASDAQ:DRRX) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -